Assessing the value for money of pharmaceuticals in New Zealand--PHARMAC's approach to cost-utility analysis.
about
The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important differenceThe Fear Reduction Exercised Early (FREE) approach to low back pain: study protocol for a randomised controlled trial.Comment on "ahead of its time? Reflecting on New Zealand's Pharmac following its 20th anniversary" : clarification from PHARMAC: PHARMAC takes no particular distributive approach (utilitarian or otherwise).
P2860
Assessing the value for money of pharmaceuticals in New Zealand--PHARMAC's approach to cost-utility analysis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Assessing the value for money ...... oach to cost-utility analysis.
@en
Assessing the value for money ...... oach to cost-utility analysis.
@nl
type
label
Assessing the value for money ...... oach to cost-utility analysis.
@en
Assessing the value for money ...... oach to cost-utility analysis.
@nl
prefLabel
Assessing the value for money ...... oach to cost-utility analysis.
@en
Assessing the value for money ...... oach to cost-utility analysis.
@nl
P2093
P1476
Assessing the value for money ...... roach to cost-utility analysis
@en
P2093
Paul Alexander
Rachel Grocott
Rachel Werner
Scott Metcalfe
P407
P577
2013-07-12T00:00:00Z